scholarly journals Type I Interferons as Regulators of Human Antigen Presenting Cell Functions

Toxins ◽  
2014 ◽  
Vol 6 (6) ◽  
pp. 1696-1723 ◽  
Author(s):  
Sandra Gessani ◽  
Lucia Conti ◽  
Manuela Del Cornò ◽  
Filippo Belardelli
2021 ◽  
Vol 18 (3) ◽  
pp. 1014-1025
Author(s):  
Elizabeth S. Levy ◽  
Ryan Chang ◽  
Colin R. Zamecnik ◽  
Miqdad O. Dhariwala ◽  
Lawrence Fong ◽  
...  

1996 ◽  
Vol 88 (1-2) ◽  
pp. 39-47 ◽  
Author(s):  
Belkys A. Maletto ◽  
Adriana Gruppi ◽  
Gabriel Moron ◽  
Maria C. Pistoresi-Palencia

2019 ◽  
Vol 97 (8) ◽  
pp. 1139-1153
Author(s):  
Chiara Chiozzini ◽  
Eleonora Olivetta ◽  
Massimo Sanchez ◽  
Claudia Arenaccio ◽  
Flavia Ferrantelli ◽  
...  

Vaccines ◽  
2020 ◽  
Vol 8 (1) ◽  
pp. 67 ◽  
Author(s):  
Sanne Burkert ◽  
Ralf R. Schumann

Tuberculosis (TB) is still an important global threat and although the causing organism has been discovered long ago, effective prevention strategies are lacking. Mycobacterium tuberculosis (MTB) is a unique pathogen with a complex host interaction. Understanding the immune responses upon infection with MTB is crucial for the development of new vaccination strategies and therapeutic targets for TB. Recently, it has been proposed that sensing bacterial nucleic acid in antigen-presenting cells via intracellular pattern recognition receptors (PRRs) is a central mechanism for initiating an effective host immune response. Here, we summarize key findings of the impact of mycobacterial RNA sensing for innate and adaptive host immunity after MTB infection, with emphasis on endosomal toll-like receptors (TLRs) and cytosolic sensors such as NLRP3 and RLRs, modulating T-cell differentiation through IL-12, IL-21, and type I interferons. Ultimately, these immunological pathways may impact immune memory and TB vaccine efficacy. The novel findings described here may change our current understanding of the host response to MTB and potentially impact clinical research, as well as future vaccination design. In this review, the current state of the art is summarized, and an outlook is given on how progress can be made.


2009 ◽  
Vol 123 (1) ◽  
pp. 74-81.e1 ◽  
Author(s):  
Nobuhiro Nakano ◽  
Chiharu Nishiyama ◽  
Hideo Yagita ◽  
Akemi Koyanagi ◽  
Hisaya Akiba ◽  
...  

Vaccines ◽  
2019 ◽  
Vol 7 (1) ◽  
pp. 22 ◽  
Author(s):  
Beatriz Escudero-Pérez ◽  
César Muñoz-Fontela

Filoviruses, such as Ebola and Marburg virus, encode viral proteins with the ability to counteract the type I interferon (IFN-I) response. These IFN-I antagonist proteins are crucial to ensure virus replication, prevent an antiviral state in infected and bystander cells, and impair the ability of antigen-presenting cells to initiate adaptive immune responses. However, in recent years, a number of studies have underscored the conflicting data between in vitro studies and in vivo data obtained in animal models and clinical studies during outbreaks. This review aims to summarize these data and to discuss the relative contributions of IFN-α and IFN-β to filovirus pathogenesis in animal models and humans. Finally, we evaluate the putative utilization of IFN-I in post-exposure therapy and its implications as a biomarker of vaccine efficacy.


Sign in / Sign up

Export Citation Format

Share Document